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ABSTRACT
Objective To assess the impact of iterative changes in
preoperative and postoperative biopsy techniques on the
outcomes of men undergoing the precision prostatectomy
procedure. Precision prostatectomy is a novel surgical
treatment for prostate cancer that aims to maximally
preserve erectogenic nerves via partial preservation of the
prostate capsule.
Design Retrospective.
Setting Single tertiary care center.
Participants This study included 120 patients who
consented to undergo prostate cancer treatment with
the precision prostatectomy procedure. Patients were
originally enrolled in one of two separate prospective
protocols studying precision prostatectomy.
Interventions Preoperatively, 60 patients were
screened with transrectal (TR) biopsy and 60 were
screened by transperineal (TP) biopsy. Ultimately, 117
patients underwent precision prostatectomy. Of the 43
postoperative biopsies, 19 were TR; 17 were TP with
ultrasound; and 7 were TP with microultrasound (mUS).
Main outcome measures Preoperatively, we evaluated
whether the transition to TP biopsy was associated with
differences in postoperative treatment failure defined as
a neoplasm-positive postoperative biopsy. Postoperative
biopsies were compared with respect to their ability to
sample the remnant tissue, specifically percentage of
cores positive for prostate tissue.
Results Preoperatively, 9/60 (15%) positive
postoperative biopsies occurred in the TR group and
6/60 (10%) in the TP group; Kaplan-Meier survival
estimates did not differ between groups (p=0.69 by log
rank). Postoperatively, the numbers of cores positive for
prostate tissue were 99/160 (62%), 63/107 (59%), and
36/39 (92%) in the TR biopsy, TP with ultrasound, and
TP with mUS groups, respectively; this difference was
statistically significant versus the rate in the TR and
standard TP groups (p=0.0003 and 0.0002).
Conclusion We found no significant improvement in
patient screening, preoperatively—though limited by
small sample size and relatively short follow-up. The
incorporation of high-frequency mUS for postoperative
biopsies improved the ability to sample the remnant tissue
with a higher efficiency.

WHAT IS ALREADY KNOWN ABOUT THIS
SUBJECT?
⇒ Precision prostatectomy is a novel surgical subto-

tal procedure that removes ~95% of the prostate
with complete removal of the side with a lesion and
spares a sliver of prostatic capsule and the seminal
vesicle on the contralateral side.
⇒ Transrectal (TR) biopsies have been used to screen
patients for candidacy for the procedure by sampling the prostatic tissue planned to be left in situ
and postoperatively to sample the prostatic remnant
in the setting of elevated prostate-specific antigen.

WHAT ARE THE NEW FINDINGS?
⇒ Transitioning from TR biopsies to standard tran-

sperineal (TP) biopsy preoperatively and to high-
resolution microultrasound-
guided TP biopsy
postoperatively served as important facets that may
have improved patient screening for the precision
prostatectomy and were shown to better assess for
residual cancer postoperatively.

HOW MIGHT THESE RESULTS AFFECT FUTURE
RESEARCH OR SURGICAL PRACTICE?
⇒ Optimization of the oncological/functional trade-off

via refined biopsy procedures within the precision
prostatectomy may increase adoptability.

INTRODUCTION
Whole gland treatment with either radical
prostatectomy or radiation therapy represents
the standard of care for the management of
grade group 2 or higher clinically localized
prostate cancer.1 2 Although effective at eradicating disease, these treatments are associated with high rates of urinary and sexual
side effects. For example, in the ProtecT trial,
which compared active surveillance, radical
prostatectomy, and radiation therapy, only
14.6% of men reported the ability to obtain
an erection firm enough for intercourse
1 year following radical prostatectomy (preoperative baseline rate of 65.7%).3 Similarly, in
men who underwent radiation therapy, this
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figure was 37.6% (baseline of 68.4%). Furthermore, in
a large meta-analysis examining continence outcomes,
Ficarra et al found 1-year incontinence rates for robotic
radical prostatectomy ranged from 4% up to 31% using
a ‘no pad’ definition.4 These same findings have been
corroborated in other high-quality reports in the urological literature.5 6
The unfavorable side effect profile of whole gland treatments has motivated the development of targeted, or
focal, treatments for prostate cancer, which aim to avoid
damage to the anatomical structures that allow for erectile
function and urinary control. To date, these efforts have
largely focused on the use of ablative technologies such
as high-intensity focus ultrasound, cryotherapy, photodynamic therapy, and laser ablation.7–9 Candidates for prostate cancer focal therapy typically have one to two regions
of cancer identified on a prostate biopsy performed with
the guidance of MRI.10 Unfortunately, due to the imperfect sensitivity of MRI for detecting sites of clinically
significant prostate cancer11 as well as issues related to the
limited sampling density that can be achieved with prostate biopsy, 10%–40% of men treated for a focal tumour
ultimately harbour multifocal sites of disease.9 As a result,
the 5-year retreatment rates for prostate focal therapy
have historically been unacceptably high in the range of
20%–30%.12–14
To address the issues outlined previously, we have developed a novel surgical technique—known as the precision
prostatectomy procedure—that aims to remove ~95% of
the prostate while maximally preserving the erectogenic
nerves that run alongside the prostate capsule.15–17 During
this procedure, men undergo a standard radical prostatectomy on one side along with a contralateral subtotal
prostatectomy, leaving the patient with several millimetre
rims of tissue that contains the erectogenic nerves. We
have previously reported the highly favorable results of 88
patients who underwent this novel procedure.17 Notably,
by 12 months postoperatively, 90% of preoperatively
potent men reported a return of erections sufficient for
intercourse. Furthermore, at 36 months of follow-up, only
7% of patients were found to harbour clinically significant
prostate cancer in their remnant prostate tissue, far less
than the historical outcomes with focal ablative therapies.
As with focal therapy, a key component for selecting
candidates for the precision prostatectomy procedure
is ensuring that the untreated portion of the patient’s
prostate is free from any cancer. This is accomplished by
performing a preoperative diagnostic biopsy aimed at
sampling the periphery of the prostate, concentrating on
the area that will be left in situ. Similarly, when assessing
the oncological success of this procedure, a postoperative
biopsy is required to evaluate for evidence of residual
disease in men with a rising or elevated prostate-specific
antigen (PSA) level.
Over the course of developing the precision prostatectomy procedure, we have made iterative changes to
our techniques for performing both preoperative and
postoperative biopsies. This included transitioning from
2

a transrectal (TR) to a transperineal (TP) approach for
preoperative prostate biopsy, a method which is known
to be associated with a lower risk of infectious complications as well as improved sampling of the peripheral
and anterior zones of the prostate.18 Additionally, we
have implemented the use of high-
frequency microultrasound (mUS) while performing postoperative TP
prostate biopsies to improve the visualization of the
small-volume remnant tissue. The aim of this study was
to use the Innovation, Development, Exploration, Assessment, Long-Term study (IDEAL) model, put forth by the
Balliol Colloquium,19 20 to assess the impact of these iterative changes to our biopsy techniques on the outcomes
of men undergoing the novel precision prostatectomy
procedure.
METHODS
All patients included in this retrospective IDEAL 2b analysis were prospectively enrolled in one of two separate
research protocols studying the precision prostatectomy
procedure (HFH-IRB#12 507 for IDEAL stage 1 and HFH-
IRB#14 531 for IDEAL stage 2b). Patients who were eligible
for precision prostatectomy had a unilateral lesion with
grade group ≤3 prostate cancer, a serum PSA ≤15 ng/mL,
clinical stage ≤cT2, and preoperative erectile function
score (International Index of Erectile Function score −5)
of ≥17 out of 25. Patients were permitted to have grade
group ≤2 disease on the contralateral side so long as it was
not contained within the capsular region to be left in situ
at the time of the precision prostatectomy.
As a first component of our study, we evaluated whether
our transition from a TR to TP approach was associated
with differences in treatment failure defined by either
intraoperative conversion to radical prostatectomy or a
postoperative biopsy containing prostate cancer. In the
second component of our study, we compared three
methods of prostate biopsy (TR, TP, and mUS-guided
biopsy) with respect to their ability to adequately sample
the prostatic remnant tissue, using percentage of cores
positive for prostate tissue as the primary endpoint.
Preoperative TR prostate biopsies were performed
with ultrasound guidance alone or with ultrasound/MRI
fusion using the UroNav platform (Invivo, Gainesville,
Florida, USA), and TP prostate biopsies were performed
with or without MRI guidance using the KOELIS Trinity
biopsy platform (KOELIS, Grenoble, France; figure 1).21
MRIs were infrequently obtained and MRI fusion only
occurred when there was an outside MRI obtained prior
to presentation. Postoperative biopsies were performed
with both methods but more recently evolved to perform
TP biopsies with the guidance of high-frequency mUS
(ExactVu, Exact Imaging, Markham, Canada; figure 2).
For-
cause postoperative biopsies were performed on
violation of the American Urological Association definition of biochemical failure (BCF) for radical prostatectomy,22 and intraoperative frozen section biopsies were
performed solely at the discretion of the treating surgeon.
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Figure 1 A) Three-dimensional reconstructed view of the
KOELIS Trinity system used for preoperative TP biopsies.
In this case, the MRI targets are the yellow spheres and
the needle throws are the green cylinders around the
circumferential edge of the prostate. (B) Ultrasound image of
a preoperative TP needle biopsy sampling the prostate. TP,
transperineal.

They were obtained always in the early stages of biopsy
development but were omitted in the setting of preoperative TP capsular biopsy that sampled the remnant. The
number of post-treatment biopsies was based on surgeon
judgment informed by adequate tissue on needle cores.
Biopsy needle throws were repeated until it was felt that
the remnant was adequately sampled and there was sufficient tissue sampled. The prostate biopsies, both preoperatively and postoperatively, were performed by two
attending surgeons (MM and WJ). There was minimal
resident and fellow involvement, all of which was appropriately supervised.
The χ2 test and Mann-Whitney U test were used to detect
differences in categorical and non-
parametric continuous variables, respectively. Additionally, in our comparison of the preoperative biopsy techniques, we used the
Kaplan-Meier method to estimate the cumulative rates of
treatment failure. Groups were compared using the log-
rank statistic. P values of 0.05 or less were considered to
indicate statistical significance. All statistical analysis was
performed in IBM SPSS Statistics for Windows V.27.0.
RESULTS
Between December 2016 and May 2021, 120 patients
were brought to the operating room with the intent of
performing a precision prostatectomy procedure. The
baseline characteristics of the study cohort are shown
in table 1. In total, 60 (50%) of the 120 men were
screened using TR prostate biopsy and 60 (50%) were

Figure 2 (A) Traditional ultrasound imaging of the prostatic
remnant. (B) High-resolution microultrasound image of the
prostatic remnant.

screened with the TP approach. Prebiopsy MRIs were
obtained from 23 patients, and of those, only 12 patients
had an MRI target and underwent fusion biopsy. Three
patients (2.5%) were converted to radical surgery based
on positive intraoperative frozen section. Of the 117
patients who underwent the precision prostatectomy,
46 patients experienced BCF, stringently defined as two
consecutive PSA values above 0.2 ng/dL after postoperative PSA nadir; 29 of these patients were screened
by TR ultrasounds and 17 were screened by TP ultrasound. Of the 46 BCRs, 27 received postoperative biopsies. The remaining 19 patients omitted biopsies via
shared decision making based on elevated but stable
(not increasing) PSA level, deemed to be due to benign
tissue left in situ. In total, 9 (15%) patients in the TR
group and 6 (10%) patients in the TP group met the
definition of treatment failure. Kaplan-
Meier survival
estimates did not differ significantly between groups
(p=0.69 by log-rank without adjustment). Figure 3 shows
the survival curves for up to 4 years for the TR group and
2.5 years for the TP group. The disparity in follow-up
is due to the lead-time in the transition to TP-screened
patients. Other endpoints used to compare the efficacy
of the preoperative biopsy included the proportion of
positive surgical margins (12/60 (20%) of the TR biopsies and 16/60 (27%) of the TP biopsies resulted in a
positive margin on the side of tissue preservation), clinically significant margins, focal margins, and multifocal
margins in the specimen removed via precision prostatectomy—all of which did not reach a statistical significant difference between biopsy techniques, with a p
value of >0.4 for all comparisons.
The primary outcome for judging the adequacy of
our postoperative biopsy technique was the percentage
of biopsy cores positive for prostate tissue. As our biopsy
method evolved in time (ie, TR to TP with standard
ultrasound and then to TP with ExactVu), we saw an
increase in our ability to sample the prostate remnant.
With the TR technique, 99 of 160 (62%) collection
cores contained prostate tissue. Similarly, with the standard TP technique, 63 of 107 (59%) cores contained the
target tissue. In contrast, on implementing TP biopsy
with high-frequency mUS guidance, the proportion of
cores containing prostate tissue rose dramatically to 36
of 39 (92%). The difference between groups was highly
significant (both comparisons p<0.001). As a secondary
endpoint, we evaluated the number of remnant biopsy
cores taken per procedure as a marker of procedural
efficiency. Surgeons took a median of 9.0 (IQR 6.0–9.0),
5.0 (IQR: 4.0–7.5), and 6.0 (IQR 4.0–6.5) cores with the
TR, standard TP, and TP with mUS biopsy procedures,
respectively. There was improved efficiency with the standard TP and mUS-guided technique, as compared with
the TR biopsy (p=0.01, 0.03), but there was no difference
between the two TP techniques (p=1.0).
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Table 1 Baseline characteristics of 120 patients who underwent screening for precision prostatectomy with either TR biopsy
or TP biopsy
TR biopsy
(n=60)

TP biopsy
(n=60)

57.5 (53.0–64.0)
28.4 (26.0–31.0)

62.0 (57.0–66.3)
28.5 (25.2–30.9)

 African–American

8 (13)

16 (27)

 Asian

1 (2)

1 (2)

 Hispanic

2 (3)

1 (2)

 Caucasian

45 (75)

37 (62)

 Other/unknown

4 (7)

5 (8)

Preoperative PSA (ng/mL), median (IQR)

5.4 (3.8–6.3)

5.9 (4.6–8.2)

 1

19 (31)

8 (13)

 2

37 (62)

34 (57)

 3

4 (7)

18 (30)

 T1

41 (68)

55 (92)

 T2

19 (32)

4 (7)

 T3

0 (0)

1 (2)

 Low

19 (32)

8 (13)

 Intermediate
 High

40 (67)
1 (2)

52 (87)
0 (0)

Age (years), median (IQR)
BMI (kg/m2), median (IQR)
Race, n (%)

Biopsy Gleason group, n (%)

Clinical T stage, n (%)

Clinical National Comprehensive Cancer Network (NCCN) risk, n (%)

BMI, body mass index; PSA, prostate-specific antigen; TP, transperineal; TR, transrectal.

DISCUSSION
In this study, we examined the impact of iterative changes
to our preoperative and postoperative biopsy techniques
on the outcomes of patients undergoing the precision
prostatectomy procedure. Our preoperative change
from TR to TP biopsy did not statistically improve patient
screening for the precision prostatectomy. Postoperatively, this change did not improve diagnostic remnant

Figure 3 Kaplan-Meier survival curve comparing
transperineal and transrectal preoperative screening biopsy,
with respect to their ability to avoid treatment failure defined
as neoplasm-positive postoperative biopsy.

4

sampling in terms of number of cores containing prostate
tissue. We did, however, find an improved diagnostic yield
on implementing the postoperative use of high-frequency
mUS guidance, which improved our efficiency of postbiopsy tissue sampling (ie, less cores needed to adequately
sample the gland).
Historically, diagnostic prostate biopsy has been
performed via a TR approach. Because this procedure
requires the biopsy needle to puncture the rectal wall on
its trajectory to the prostate, TR prostate biopsy carries
with it a substantial risk of infectious complications.23–25
In contrast, TP prostate biopsy, which is performed percutaneously, is associated with a marked reduction in postbiopsy infections.26–30 Based on the historically favorable
safety profile with TP prostate biopsy, we opted to incorporate this technique into our clinical practice. A second
motivation for this change was the purported benefits
of improved prostate sampling with the TP approach.
More specifically, TP prostate biopsy is better suited for
anterior zone sampling, an area of the gland where prostate cancers are inadequately sampled with TR prostate
biopsy.31–33 TP prostate biopsy also appears to allow for
improved sampling of small Prostate Imaging Reporting
& Data System (PI-
RADS) of three and four lesions
regardless of anatomical location as well as higher rates of
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disease reclassification among men on active surveillance
for low-risk prostate cancer.34
Based on the data presented earlier and other similar
results, we hypothesized that the transition to TP prostate
biopsy would allow for improved sampling of the gland
ahead of the precision prostatectomy procedure and in
turn lead to a lower risk of post-treatment failure. Given
the results of our analysis, this does not appear to be true.
Although there was a 33% reduction in the hazard of
postoperative treatment failure, this difference did not
meet the conventional threshold for statistical significance. It is, however, possible that the relatively small
number of patients and the lag in follow-up for the TP
group made this analysis prone to type II error. Moreover,
the TR group had a higher proportion of men with grade
group 1 prostate cancer, placing them at an overall lower
risk of recurrence.
The role of post-
treatment biopsy among patients
undergoing the precision prostatectomy procedure is
distinct from its preoperative counterpart. The indication
for a postoperative biopsy is any rise in PSA concerning
for treatment failure. However, during the precision prostatectomy, a sliver of prostatic tissue is intentionally left in
situ, so a non-zero postoperative PSA is possible in cases
of treatment success. Given this was a new procedure,
we assumed a conservative posture with respect to BCF,
adopting the American Urological Association (AUA)
definition after radical prostatectomy. Although there is
some PSA-producing prostate tissue in situ, the median
PSA at 24 months was 0.0 IQR (0.0–0.3) in the first 88
patients.17 Thus, we believe that the AUA definition is
stringent but appropriate; as the data matures, the biopsy
criteria may evolve as patients with stable but elevated
PSA may not need a biopsy. Nevertheless, it is critical to
be able to adequately sample the prostatic remnant to
discern a benign PSA elevation from one due to cancer.
Although seemingly a simple task, because of the small
size of the remnant prostate tissue (ie, ~1 to 5 g) and the
limited resolution of most TR ultrasound units, this has
proven challenging.
Initial attempts at targeting of the capsular remnant via
a TR approach resulted in a median of 9.0 cores taken per
case with 62% of cores positive for prostate tissue. Our
switch to the TP approach improved this significantly,
with a median of 5.0 cores taken per case and 59% of
cores positive for prostate tissue. This was refined with the
introduction of the ExactVu high-resolution mUS system,
which provided superlative real-
time image resolution
by virtue of its use of a 29 MHz linear TR probe to the
image the prostate. In contrast, most standard TR ultrasound probes allow for imaging at a maximum of 14–16
MHz. TP prostate biopsy with ExactVu guidance allowed
for precise targeting of remnant tissue and resulted in a
median of 6.0 cores per cases with 92% cores positive for
prostate tissue. Importantly, there were fewer cores taken
per case with the mUS-guided biopsy. This is because the
surgeon was more confident that they properly sampled
the remnant intraoperatively when using the mUS and

TP biopsies as opposed to the standard US-guided TR
biopsies. Previously, more needle throws were required to
acquire tissue cores due to poorer visualization with the
lower definition. The lower number of cores speaks to the
efficacy of the mUS visualization, though there could be
some learning curve bias as it was adopted in the latter
stages of technique development. The increased efficiency’s relation to sampling accuracy has clinical implications in the setting of treatment failure. When the entire
remnant is more confidently sampled, then clinically
significant cancer is more confidently ruled out when the
biopsy is negative. This in turn informs the postoperative
management decision in the setting of PSA rise, as it can
be ascribed to secretion from benign prostate tissue. As an
adjunct, the use of MRI in the postoperative setting was
considered but never implemented, given the inability
to produce real-time actionable images. Moreover, there
is evidence that mUS is equivalent or better at detecting
clinically significant cancer than MRI-fusion biopsies.35–38
This study has several limitations worthy of mention.
These include its retrospective design and small sample
size. Furthermore, changes made to our postoperative
biopsy technique may have influenced our readout of
success in terms of the pretreatment biopsy technique.
More specifically, because pretreatment biopsy success
was measured by post-
treatment biopsy positivity for
cancer, improvements in the post-
treatment biopsy
method may have skewed our analysis. It is plausible that
shortcomings in our initial post-treatment biopsy method
led to false-negative biopsy results in the pretreatment TR
prostate biopsy group leading to incorrectly accepting
the null hypothesis in our analysis of pretreatment biopsy
technique.

CONCLUSION
In this retrospective IDEAL phase IIb study, we evaluated the impact of iterative changes to our pretreatment
and post-treatment biopsy techniques on the outcomes
of men undergoing the novel precision prostatectomy
procedure. The transition from TR to TP prostate biopsy
did not improve the selection of candidates for precision
prostatectomy or our ability to postoperatively sample
the remnant biopsy tissue. However, our incorporation
of high-
frequency mUS for postoperative biopsies did
lead to an improved ability to sample the remnant prostate tissue with a higher degree of efficiency. Based on
the results of this analysis, we feel no additional iterative
changes to our biopsy technique are warranted and the
presented biopsy methods (ie, preoperative TP biopsy
with KOELIS Trinity and postoperative TP biopsy with
ExactVu) will be employed in future planned randomized trials comparing precision prostatectomy to other
forms of prostate cancer treatment such as ablative focal
therapy and radical prostatectomy.
Twitter Ralph Grauer @GrauerRalph and Mohit Butaney @MohitButaney
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